Neonatal CARD14-Associated Papulosquamous Eruption: Response to Secukinumab During Infancy

Area of Science:

• Dermatology
• Genetics
• Immunology

Background:

• Neonatal erythroderma presents as generalized redness and scaling at birth.
• It is a rare but serious condition requiring prompt diagnosis and management.
• Genetic factors, such as CARD14 mutations, are increasingly recognized in its etiology.

Purpose of the Study:

• To report a case of neonatal erythroderma.
• To identify the genetic basis of the condition in the presented case.
• To evaluate the efficacy of targeted biologic therapy in severe neonatal inflammatory conditions.

Main Methods:

• Case report of a 3-week-old male infant with neonatal erythroderma.
• Genetic analysis to identify mutations in the CARD14 gene.
• Treatment with secukinumab, a targeted biologic therapy.

Main Results:

• The infant was diagnosed with neonatal erythroderma.
• A heterozygous mutation in the CARD14 gene was identified as the cause.
• Successful treatment of the infant's condition with secukinumab was observed.

Conclusions:

• CARD14 gene mutations can cause neonatal erythroderma.
• Secukinumab is a potential therapeutic option for severe neonatal inflammatory skin conditions.
• Targeted biologic therapies offer a promising approach for managing rare neonatal dermatoses.